MannKind Corporation (NASDAQ: MNKD) is one of 297 publicly-traded companies in the “Bio Therapeutic Drugs” industry, but how does it compare to its rivals? We will compare MannKind Corporation to similar companies based on the strength of its earnings, institutional ownership, risk, dividends, profitability, analyst recommendations and valuation.

Analyst Recommendations

This is a breakdown of recent ratings and price targets for MannKind Corporation and its rivals, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
MannKind Corporation 2 1 1 0 1.75
MannKind Corporation Competitors 790 3130 11384 228 2.71

MannKind Corporation currently has a consensus price target of $0.92, suggesting a potential downside of 71.50%. As a group, “Bio Therapeutic Drugs” companies have a potential upside of 41.86%. Given MannKind Corporation’s rivals stronger consensus rating and higher possible upside, analysts clearly believe MannKind Corporation has less favorable growth aspects than its rivals.

Insider & Institutional Ownership

14.0% of MannKind Corporation shares are owned by institutional investors. Comparatively, 50.4% of shares of all “Bio Therapeutic Drugs” companies are owned by institutional investors. 1.6% of MannKind Corporation shares are owned by insiders. Comparatively, 16.5% of shares of all “Bio Therapeutic Drugs” companies are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Earnings and Valuation

This table compares MannKind Corporation and its rivals gross revenue, earnings per share and valuation.

Gross Revenue NetIncome Price/Earnings Ratio
MannKind Corporation $174.76 million $125.66 million -11.89
MannKind Corporation Competitors $290.00 million $35.57 million 154.05

MannKind Corporation’s rivals have higher revenue, but lower earnings than MannKind Corporation. MannKind Corporation is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.

Volatility and Risk

MannKind Corporation has a beta of 3.1, suggesting that its stock price is 210% more volatile than the S&P 500. Comparatively, MannKind Corporation’s rivals have a beta of 5.86, suggesting that their average stock price is 486% more volatile than the S&P 500.

Profitability

This table compares MannKind Corporation and its rivals’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
MannKind Corporation -155.83% -24.93% -130.34%
MannKind Corporation Competitors -5,110.46% -418.25% -40.67%

Summary

MannKind Corporation rivals beat MannKind Corporation on 9 of the 12 factors compared.

About MannKind Corporation

MannKind Corporation is a biopharmaceutical company. The Company is focused on the discovery and development of therapeutic products for diseases, such as diabetes. Its product candidate is AFREZZA, which is an inhaled insulin used to control high blood sugar in adults with type I and type II diabetes and helps in glycemic control. AFREZZA consists of a dry formulation of human insulin delivered from a portable inhaler. AFREZZA utilizes its Technosphere formulation technology. Technosphere is a drug delivery platform that may allow the oral inhalation of a range of therapeutics. Technosphere powders are based on the Company’s fumaryl diketopiperazine (FDKP), which is a potential of Hydrogen (pH)-sensitive organic molecule that self-assembles into small particles under acidic conditions. The Company has also created a range of breath-powered, dry powder inhalers. Its inhalers can be produced in both a reusable (chronic treatment) and a single-use (acute treatment) format.

Receive News & Ratings for MannKind Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MannKind Corporation and related companies with MarketBeat.com's FREE daily email newsletter.